Long-term treatment durability and safety after switching to bictegravir/emtricitabine/tenofovir alafenamide in real-world practice: a 144-week update from the BICTEL cohort

International Journal of Antimicrobial Agents · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles